ArticleCureus2024
A Rare Case of Diffuse Large B-cell Lymphoma in the Breast: Diagnostic Insights and Treatment Approaches.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Primary diffuse large B-cell lymphoma of the breast with rare growth pattern mimics lobular carcinoma: a case report.Frontiers in oncology · 2025Article
- Primary Breast Lymphoma in a Young Female: Non-Hodgkin's Diffuse Large B-Cell Lymphoma in the Presence of Intact Breast Prostheses.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL) that can occur in the breast. This case report details the case of a 48-year-old postmenopausal woman diagnosed with primary breast DLBCL after presenting with a painless, rapidly growing mass. Imaging studies, including ultrasound and mammography, indicated significant breast involvement, confirmed by histopathological analysis revealing large atypical lymphoid cells. The patient underwent the rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy regimen, achieving complete remission after four cycles. This case underscores the importance of considering breast lymphoma in differential diagnoses for breast masses and highlights the effectiveness of timely and appropriate treatment strategies. Ongoing follow-up is essential for monitoring potential recurrences, emphasizing the need for a multidisciplinary approach to managing this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.